Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role. However, current ICIs, primarily monoclonal antibodies, face significant challenges like poor tissue penetration, high production costs, and off-target effects. These limitations hinder their efficacy and accessibility.
Small molecules, big impact: Advancing immune checkpoint inhibitors for cancer retrieved 22 August 2024 from https://medicalxpress.com/news/2024-08-small-molecules-big-impact-advancing.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Aug 11, 2023Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nation's inspirational small businesses set for Small Business SaturdayKicking off in Scotland later in the year, Small Business Saturday will embark on an ambitious month-long journey across the country to celebrate the nation’s most loved independents
Read more »
Immune landscape and response to oncolytic virus-based immunotherapyOncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.
Read more »
Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomesOncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.
Read more »
Drug bypasses suppressive immune cells to unleash immunotherapyBy recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.
Read more »
New hope for prostate cancer: New form of immunotherapy could prevent resistance to hormone therapyA new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer.
Read more »
New nanoparticle-based immunotherapy delays hormone therapy resistance in prostate cancerA new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer.
Read more »